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Scope: We have previously demonstrated the anti-inflammatory and
antioxidant properties of in vitro administered Lupinus angustifolius protein hy-
drolysates (LPHs) on human peripheral bloodmononuclear cells (PBMCs). This
study aims to evaluate the safety and efficacy of a beverage containing LPHs
(LPHb) on the immune, oxidative and metabolic status of healthy subjects.
Methods and Results: In this open-label intervention, 33 participants daily
ingest a LPHb containing 1 g LPHs for 28 days. Biochemical parameters are
assayed in fasting peripheral blood and urine samples before, during (14 days)
and after LPHb ingestion. Participants’ health status and the immune and
antioxidant responses of PBMCs are also evaluated throughout the trial. The
LPHb ingestion is safe and effective in both increasing the anti-/pro-
inflammatory response of PBMCs and improving the cellular anti-oxidant
capacity. LPHb also reduces the low-density lipoprotein-cholesterol
(LDL-C)/high-density lipoprotein-cholesterol (HDL-C) atherogenic index.
LPHb effect is particularly beneficial on decreasing not only the LDL-C/HDL-C
index but also serum total cholesterol levels in the male cohort that shows the
highest baseline levels of well-known cardiovascular risk factors.
Conclusion: This is the first study to show the pleiotropic actions of a lupine
bioactive peptides-based functional food on key steps of atherosclerosis
including inflammation, oxidative stress, and cholesterol metabolism.
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1. Introduction
There is an increasing awareness of the
importance of healthy nutrition, and
the search for new food products, that
not only provide the balanced nutrients
but also beneficial health effects, has
become in a cutting-edge field in the
frame of human and animal nutrition.
In this way, many commercial products
are enriched with different components
to improve their beneficial properties.
In particular, the number of studies
based on the bio-functionality of protein
hydrolysates has dramatically increased
over the last few years.[1,2] An additional
potential benefit of protein hydrolysates
resides in their low immunogenicity,[3]
given that the protein antigenic epitopes
can be also hydrolyzed.[4] Due to an in-
creasing concern in animal welfare and
the rising environmental awareness,[5]
the consumption of vegetable products is
becoming a common trend. In this way,
a growing body of evidence has under-
lined several biological actions such as
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immune,[6,7] antioxidant[6,8] and metabolic [9–11] effects of dif-
ferent vegetable protein hydrolysates by in vitro or pre-clinical
approaches. We have previously shown that Lupinus angusti-
folius protein hydrolysates (LPHs), generated by hydrolyzation
with the commonly used food-grade endopeptidase Alcalase
2.4 L, inhibit the enzymatic activity inflammatory enzymes
phospholipase A2, cyclooxygenase 2, thrombin, and transglu-
taminase in a cell-free system.[12] Moreover, in vitro adminis-
tration of LPHs attenuated the pro-inflammatory response of
THP-1-derived macrophages.[13] Likewise, we have shown for
the first time that LPHs improve the anti-inflammatory/pro-
inflammatory cytokine balance and total antioxidant capacity
in ex vivo cultured human peripheral blood mononuclear cells
(PBMCs).[14]
Once studied the biological activity of LPHs under in vitro sys-
tem, the aim of the present study was to evaluate the safety and
efficacy of a beverage containing LPHs (LPHb) on the immune,
oxidative and metabolic status in healthy subjects by conducting
an open-label longitudinal study (Lupine-1 trial).
2. Experimental Section
2.1. Subjects
Thirty five healthy participants, 18–50 years, were recruited via
mass advertising from Seville Urban Community (Figure S1,
Supporting Information) according to the inclusion/exclusion
criteria (Table S1, Supporting Information). The sample size
of 35 subjects was calculated using the nQuery Sample Size
Calculator tool based on the normal distribution of the studied
parameters in the population. A minimum expected difference
of 5% has been set between before and after the interven-
tion, with an expected standard deviation between the means
of 10%. Considering an error 𝛼 = 5% and a 𝛽 error of 85%
(power) an estimated loss percentage of 5%, the minimum
number of subjects required for the study was 35. The study
was conducted between October 2015 and December 2015,
and all the procedures were in accordance with the Helsinki
Declaration of 1975, as revised in 1983. The clinical trial
“Lupine-1” was approved by the ethical review board of Virgen
Macarena and Virgen del Rocío University Hospital (reference
number 2015/110). Written informed consent was obtained
from all participants. This clinical study was declared to the
website ClinicalTrials.gov under the number NCT02590887
(https://clinicaltrials.gov/ct2/show/NCT02590887).
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Figure 1. Experimental study scheme. Schematic representation of the dif-
ferent phases of the study. The open-label longitudinal study lasted 28 days
in which the volunteers daily consumed 200 mL of experimental beverage
containing 1 g LPHs. On days 0, 14, and 28, the volunteers were called
on different experimental approaches. LPHb, LPHs-based functional bev-
erage; LPHs, lupine protein hydrolysates; n, number of volunteers.
2.2. Study Design
Thirty five healthy participants were enrolled in an open-label
longitudinal study. Thirty three subjects [16 males; mean age
30.53 (±2.71); 17 females; mean age 30.47 (±2.27)] completed the
trial (Figure 1). Before the first LPHb intake, fasting peripheral
blood and urine samples as well as the Short Form-36 (SF-36)
health survey were collected from every participant to establish
the baseline parameters of the study. Biological samples and
Likert scale were also collected on days 14 and 28 (end of study),
whereas SF-36 health survey was collected at the end of the
study. Blood collection was carried out between 08:00 and 09:00
am in the Department of Clinical Biochemistry of Virgen del
Rocío University Hospital, Seville. Blood samples were drawn
in VACUETTE Z Serum Sep Clot Activator tubes (Greiner
Bio-one, Kremsmünster, Austria) for analysis of biochemical
parameters; in VACUETTE K3EDTA tubes (Greiner Bio-one)
for a white blood cell count; and in Vacutainer CPT tubes (BD
Biosciences, San Jose, CA, USA) for the subsequent PBMCs
isolation. First morning urine was collected in VACUETTE
urine tubes (Greiner Bio-one). In order to prevent a bias in
the results caused by changing the volunteers’ habits, sub-
jects were instructed not to modify their dietary and physical
habits.
2.3. Preparation of the Study Product
LPHs were obtained and characterized (chemical composition
and the degree of hydrolysis) as previously described in details.[14]
The LPHb consisted in an emulsion of 95% (w/w) aqueous
phase (AP) and 5% oil phase (OP). The AP contained equal vol-
umes of solution A and B. Solution A was an aqueous solu-
tion made up of LPHs (1% w/w), sucrose (12% w/w), vanilla
flavor (0.36% w/w) and drinking water (86.64% w/w) whereas
Solution B was an aqueous solution composed of xanthan gum
(0.25% w/w) and drinking water (99.75% w/w). Solution B was
prepared aiming to disperse xanthan gum in hot water (80°C)
with a gentle agitation for 1 h. Once completely dissolved, xan-
than gum was cooled down at room temperature and preserved
during 24 h for an optimum hydration. OP was entirely com-
posed of refined sunflower oil. The final emulsion was obtained
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from two steps. First, pre-emulsion was made by slowly adding
the OP into the AP and homogenizing by a T-25 basic ULTRA-
TURRAX (IKA-Werke GmbH & Co. KG, Staufen, Germany) at
8000 rpm. Subsequently, the pre-emulsion was passed through
an Emulsiflex-2000-B3 high-pressure homogenizer (Avestin Inc.,
Ottawa, Canada) at 70,000 psi (4.83 × 108 Pa) to make the final
beverage. The LPHb was packaged by PULEVA (Lactalis, France)
in 200 mL sterile tetrabricks, according to Spanish and European
food regulation (RD 135/2010). Table S2, Supporting Informa-
tion shows the composition of the administered formulation to
volunteers.
2.4. Dosage Information
Volunteers daily consumed a fasting single dose of 200 mL of
LPHb (one tetrabrick) for a period of 28 days between 08:00
and and 10:00 am. LPHs concentration was selected based on
previous internal tests. The concentration of LPHs was not
achievable through a regular diet or food supplements.
2.5. Biochemical Measurements
Biochemical parameters were quantified in serum from fasting
blood samples as previously described,[15,16] by an automated
immunoassay electrochemiluminescence systems (COBAS c702
and e602 analyzers; Roche Diagnostic, Basel, Switzerland); white
blood cells were quantified in blood samples by fluorescence flow
cytometer SYSMEX XE 5000 Hematology Analyzer (Sysmex Eu-
rope GmbH, Norderstedt, Germany). Urine samples were an-
alyzed by Beckman Coulter AU2700 (Beckman Coulter, Brea,
USA).
2.6. Participants’ Health Status
SF-36 health survey was filled out by all participants to evaluate
their physical and mental health status before (day 0, baseline)
and at the end of the study (day 28). The SF-36 measured the
health status in eight dimensions that evaluated physical health
(physical functioning, role limitation due to physical health,
pain, and general health) and mental health (social function-
ing, role limitation due to emotional problems, energy/fatigue,
and emotional well-being). Total score on each SF-36 dimension
ranged between 0 and 100, a higher score indicated a healthier
state.[17]
2.7. Analysis of LPHb Palatability
ALikert type scale was conducted to estimate the degree of palata-
bility of LPHb. The scale was applied to all participants on days 14
and 28. A 7-items scale was performed with the following scoring
system: 1, extremely unpalatable; 2, quite unpalatable; 3 slightly
unpalatable; 4, neutral taste; 5, slightly palatable; 6, quite palat-
able; 7, very palatable.
2.8. Cell Cultures
PBMCs were isolated by centrifugation of Vacutainer CPT
tubes, and then cultured at a density of 1 × 106 cells mL-1 in
RPMI-1640 supplemented with 10% fetal bovine serum, 2 mM
l-glutamine and 50 U mL-1 of penicillin/streptomycin (all from
BioWest, Nuaillé, France). To evaluate the antioxidant activity,
cells were cultured overnight, while they were cultured for
cytokine quantification for 48 h in the presence of 8 µg mL-1
phytohemagglutinin-P (PHA; Sigma-Aldrich, St. Louis, MO,
USA), a well-known selective T cell mitogen, and incubated at
37 °C in a 5% CO2 humidified atmosphere. Supernatants were
collected and stored at −20 °C until use.
2.9. Extracellular Cytokine Quantification
Cytokine production was quantified in supernatants of cultured
PBMCs by using a fluorescent bead multiples assay (Human
13plex Kit FlowCytomix; eBioscience, San Diego, CA, USA) ac-
cording to the manufacturer’s instructions. Median fluorescence
intensity data were obtained using a Canto II flow cytometer (BD
Biosciences) and analyzed with FlowCytomix Pro 2.4 software
(eBioscience).
2.10. Antioxidant Capacity
TAC was quantified in the supernatants from overnight cultured
PBMCs by the OxiSelect Total Antioxidant Capacity Assay Kit
(Cell Biolabs, San Diego, CA, USA), according to the manufac-
turer’s instructions. Briefly, this assay was based on the reduc-
tion of copper (II) due to the presence of antioxidant molecules.
The absorbance was measured at 490 nm with a Tecan Infinite
200 PRO microplate reader (Tecan, Männedorf, Switzerland).
Data were expressed as “µM copper reducing equivalents” (CRE),
which were proportional to the TAC sample.
Oxygen radical absorbance capacity (ORAC) assay was per-
formed in supernatants from overnight-cultured PBMCs (sam-
ple dilution was 1:400 in phosphate buffer; 75 mM, pH 7.4) ac-
cording to Ou et al.[18] The fluorescence (excitation: 485/20 nm,
emission: 528/20 nm) was calculated every 5 min for 90 min
with the Synergy HT-multimode microplate reader (Biotek In-
struments, Winooski, VT, USA). Final ORAC values were ex-
pressed as “mmoles of Trolox equivalents/mL”.
2.11. Statistical Analysis
Results were expressed as the mean and standard error of the
mean (SEM). Non-normally distributed variables were analyzed
by non-parametric Friedman or Wilcoxon paired tests, whereas
normally-distributed ones (TAC andORAC) were analyzed by the
parametric Student’s t-test, using IBM SPSS Statistics software




This study was conducted in a final sample of 33 subjects out of
the 35 subjects recruited, encompassing 16 males (48.48%) and
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Table 1. Demographic characteristics of the study participants.
Males Females Total
Number 16 17 33
Age 30.53 ± 2.71 30.47 ± 2.27 30.27 ± 1.72
BMI 23.77 ± 0.76 21.71 ± 0.31 22.71 ± 0.43
Number of participants, age (years), and body mass index (BMI) of the study partic-
ipants. Data present the mean ± standard error of the mean for each group.
17 females (51.52%). No significant differences (p > 0.05) in the
age and bodymass index (BMI) betweenmales and females were
observed at baseline (Table 1). After 28 days of intake no impact
in the weight of volunteers was observed (day 0: 65.81 ± 1.94 kg;
day 28: 66.16 ± 1.95 kg; p = 0.082).
3.2. Safety Study
To test the LPHb safety (side effects or discomfort) we have
evaluated the change (between baseline, 14 days and after
LPHb ingestion) of the general, hepatic, renal and immune
biochemical markers (Tables 2–6) as well as the white blood cell
counts (hemogram) (Table 7). In addition, SF-36 health survey
was performed to test the volunteers´ perception about their
physical and mental health before and after 28d LPHb ingestion
(Table 7). The baseline levels of the studied biochemical markers
were within the normal range and no changes (p > 0.05) were
observed either in the general (Table 2), hepatic (Table 3), renal
(Table 4) and immune (Table 5) biochemical profiles, or in the
white blood cell counts (Table 6) after 28 days of LPHb ingestion.
In addition, no variations (p > 0.05) in the SF-36 health survey
(physical and mental health) of the volunteers between the
baseline and the endpoint of the study were observed (Table 7).
Thus, no side effects on their metabolism (biochemical markers)
or in the global health status perception (SF-36) were observed.
Moreover, no adverse effect or discomfort was reported by any
of the participants during or after the end of the study.
3.3. LPHb Palatability
To assess the acceptability of the LPHb, the widely used Lik-
ert scale was completed to estimate the degree of palatability of
the beverage. As is shown in Table S3, Supporting Information,
Likert scale scoring indicated an increase in the LPHb accep-
tance over the course of the study with a mean Likert score of
4.06 ± 0.21 at the end of the study (p = 0.012).
3.4. LPHb Effects on Blood Lipid Biochemical Markers
LPHb ingestion for 28 days did not modify (p > 0.05) the serum
concentrations of total cholesterol (TC), high-density lipoprotein-
cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C)
and triglycerides (TG). However, the LPHb treatment signifi-
cantly reduced (p ≤ 0.05) the LDL-C/HDL-C ratio in the total
population. This was due to the significant decrease (p ≤ 0.01) of
LDL-C/HDL-C levels in the male participants (Table 8). We also
found that the LPHb effect on the reduction of LDL-C/HDL-C
ratio was significant in males with high baseline levels (defined
as baseline values above the median; M2) of cardiovascular
risk factors such as BMI (p ≤ 0.05), TC (p ≤ 0.05), LDL-C (p ≤
0.05), Castelli risk index I (TC/HDL-C ratio) (p ≤ 0.05) and II
(LDL-C/HDL-C ratio) (p≤ 0.01), and atherogenic index of plasma
[(Log(TG/HDL)] (p ≤ 0.05), whereas no differences (p > 0.05)
were observed in those whose baseline levels were under the me-
dian (M1) (Figure 2). Moreover, LPHb consumption significantly
decreased the TC levels in males with higher baseline values of
BMI (p ≤ 0.05), TC (p ≤ 0.05), LDL-C (p ≤ 0.05), and Castelli risk
index II (p≤ 0.05), (Figure 2A–C,E, respectively). Likewise, males
with baseline levels of LDL-C and Castelli risk index II in the M2
showed significantly lower (p ≤ 0.05) serum concentrations of
LDL-C after 28 days of LPHb consumption (Figure 2C,E).
3.5. LPHb Efficacy on PBMCs Immune Response
To analyze the immune effects of the 28 days-ingestion of LPHb
on PBMCs from participants, the levels of key pro-inflammatory
Th1 [interleukin (IL)-2, interferon-𝛾 (IFN-𝛾) and tumor necro-
sis factor (TNF)] and anti-inflammatory Th2 (IL-4 and IL-10) cy-
tokines were quantified in the supernatants of PHA-stimulated
PBMCs. As shown in Figure 3, LPHb significantly diminished
the Th1 pro-inflammatory response by reducing the production
of IL-2 (p ≤ 0.01) (Figure 3A), IFN-𝛾 (p ≤ 0.05) (Figure 3B), and
TNF (p ≤ 0.01) (Figure 3C). Although the production of the Th2
cytokines, IL-4 and IL-10 was not modified by LPHb treatment
(p > 0.05) (Figure 3D,E, respectively), a significant increase in
the ratios of IL-10/IFN-𝛾 (p ≤ 0.05), IL-10/TNF (p ≤ 0.05), and
IL-4/TNF (p ≤ 0.01) was observed after the 28 days-LPHb con-
sumption (Figure 3G,H,K, respectively).
Table 2. General biochemical parameters.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
Glucose (mg dL−1) 70-110 89.13 ± 1.82 87.87 ± 1.85 90.44 ± 1.91 83.35 ± 2.56 84.94 ± 2.02 85.59 ± 2.00 86.06 ± 1.66 86.36 ± 1.38 87.94 ± 1.43
Urea (mg dL−1) 10-40 33.33 ± 1.83 31.06 ± 1.23 32.75 ± 1.58 29.94 ± 1.76 27.23 ± 1.74 28.29 ± 1.73 31.58 ± 1.29 29.09 ± 1.11* 30.45 ± 1.22
Creatinine (mg dL−1) 0.5-1.1 0.90 ± 0.02 0.91 ± 0.02 0.90 ± 0.25 0.74 ± 0.02 0.75 ± 0.02 0.77 ± 0.02 0.82 ± 0.02 0.83 ± 0.02 0.84 ± 0.02
Insulin (µU mL−1) 2.5-25 8.21 ± 1.50 7.13 ± 0.68 8.90 ± 0.97 8.04 ± 0.97 7.29 ± 0.64 8.82 ± 0.90 8.13 ± 0.88 7.21 ± 0.46 8.86 ± 0.65
Data present the mean ± standard error of the mean of the basic biochemical parameters for each group and time point. Friedman test was applied to determine intergroup
differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline). *p ≤ 0.05.
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Table 3. Hepatic biochemical parameters.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
Total Protein
(g dL−1)
6.5-8.0 7.71 ± 0.09 7.32 ± 0.09** 7.57 ± 0.10 7.25 ± 0.08 7.11 ± 0.92 7.16 ± 0.06 7.46 ± 0.07 7.21 ± 0.06** 7.36 ± 0.07
ALP (U L−1) 40-130 63.00 ± 4.41 62.06 ± 3.49 65.06 ± 3.75 48.00 ± 3.02 50.00 ± 3.53 49.47 ± 3.13 55.27 ± 2.92 55.85 ± 2.67 57.03 ± 2.76
GGT (UI L−1) 10-50 16.60 ± 1.21 14.94 ± 0.99** 15.50 ± 1.10 12.23 ± 1.15 11.06 ± 1.18* 11.71 ± 1.23 14.28 ± 0.91 12.94 ± 0.84*** 13.54 ± 0.88
GOT (U L−1) 10-37 19.31 ± 1.09 18.27 ± 1.14 20.60 ± 1.85 17.29 ± 0.95 16.59 ± 0.85 15.65 ± 1.04 18.27 ± 0.73 17.37 ± 0.71 17.97 ± 1.10
GPT (UI L−1) 10-40 17.93 ± 1.53 17.94 ± 2.12 19.64 ± 1.97 13.59 ± 1.41 13.53 ± 1.07 14.12 ± 1.76 15.62 ± 1.09 15.67 ± 1.21 16.61 ± 1.39
Data present the mean ± standard error of the mean of the total protein and the transaminases values for each group and time point. Friedman test was applied to determine
intergroup differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline). ALP,
alkaline phosphatase; GGT, gamma-glutamyltransferase; GOT, glutamic-oxaloacetic transaminase; GPT glutamic-pyruvic transaminase. *p ≤ 0.05; **p ≤ 0.01 and ***p ≤
0.001.
Table 4. Renal biochemical parameters.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
Protein/Creatinine
(mg dL−1)
0–0.2 0.054 ± 0.003 0.052 ± 0.002 0.053 ± 0.004 0.065 ± 0.003 0.062 ± 0.004 0.062 ± 0.003 0.062 ± 0.003 0.062 ± 0.003 0.058 ± 0.002
Urea/Creatinine
(mg dL−1)
12-20 13.93 ± 0.89 12.77 ± 0.81 13.61 ± 0.82 13.98 ± 1.04 12.97 ± 1.08 13.72 ± 0.88 13.95 ± 0.67 12.87 ± 0.67 13.67 ± 0.59
Data present the mean ± standard error of the mean of the renal biochemical parameters ratios for each group and time point. Friedman test was applied to determine
intergroup differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline).
3.6. LPHb Efficacy on Antioxidant Capacity
To evaluate whether the LPHb ingestion was able to modify
the PBMCs antioxidant status, TAC and ORAC assays were per-
formed in the supernatant of overnight-cultured cells. After 28
days of daily LPHb consumption, a significant increase in both
TAC (p ≤ 0.05) (Figure 4A) and ORAC (p ≤ 0.05) (Figure 4B) ac-
tivities was observed in the PBMCs of participant subjects.
4. Discussion
This study shows that 4 weeks of daily ingestion of LPHb is safe
and effective at increasing the anti-inflammatory and antioxidant
responses in circulating blood leukocytes from healthy subjects.
In addition, LPHb consumption reduces the LDL-C/HDL-
C atherogenic index, a predictive factor for atherosclerosis
effects.[19,20] Interestingly, the LPHb intake was particularly ben-
eficial in decreasing not only the LDL-C/HDL-C index but also
serum TC levels in males who showed high baseline levels of
well-known cardiovascular risk factors such as BMI, TC, LDL-C,
Castelli risk index I and II and the atherogenic index of plasma.
Moreover, the good sensorial acceptability of the LPHb, tested by
the Likert scale, allowed to successfully comply with the study.
Despite the presence of the fatty and glucidic content (5% oil
and 6% sucrose, respectively) in the LPHb, after 28 days of intake
no impact in the weight of volunteers was observed. Also, neither
lipid nor glucidic biochemical parameters increased after LPHb
consumption. Although each LPHb tetrabrick contained 1 g of
LPHs, no changes in the total protein levels were observed after
the beverage ingestion. Additionally, hepatic, renal, and immune
biochemical markers were not altered throughout the 28 days.
Although some proteins from Lupinus spp. have been described
to trigger an allergic response,[21] no effect on the blood levels of
C-reactive protein and immunoglobulin (Ig) G, IgA, IgM or IgE, a
marker of food allergy,[22] was observed after LHPb consumption.
In accordance with these findings, the consumption of LPHb
did not affect the volunteers’ perception of their own health sta-
tus, manifesting a general healthy self-perception at the end of
Table 5. Immune biochemical parameters.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
CRP (mg L−1) 0-5 0.73 ± 0.12 0.72 ± 0.14 0.77 ± 0.15 1.49 ± 0.40 0.78 ± 0.15 2.82 ± 0.67 1.09 ± 0.20 0.75 ± 0.10 1.79 ± 0.39
IgG (mg dL−1) 700-1600 1258.64 ± 51.98 1229.69 ± 52.74 1259.89 ± 52.52 1214.12 ± 43.45 1196.09 ± 51.93 1185.97 ± 49.83 1234.99 ± 33.25 1212.38 ± 42.35 1221.81 ± 36.18
IgA (mg dL−1) 70-400 282.33 ± 21.00 276.05 ± 20.26 282.81 ± 21.19 239.78 ± 21.86 241.38 ± 21.35 241.57 ± 20.96 259.72 ± 15.46 258.19 ± 14.84 261.56 ± 15.12
IgM (mg dL−1) 40-230 111.37 ± 9.45 108.36 ± 8.82 111.62 ± 9.05 145.54 ± 11.37 139.75 ± 9.84 139.79 ± 9.69 129.52 ± 7.98 124.53 ± 7.09 126.13 ± 7.00
IgE (mg dL−1) 0-100 58.23 ± 16.95 54.65 ± 13.75 60.83 ± 14.76 52.85 ± 18.46 48.69 ± 16.33** 48.80 ± 16.49 55.54 ± 12.32 51.67 ± 10.50** 54.82 ± 10.93
Data present the mean± standard error of the mean of the C-reactive protein (CRP) and the immunoglobulins (Ig) values for each group and time point. Friedman test was applied to determine intergroup
differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline). **p ≤ 0.01.
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Table 6. Hemogram.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
Leukocyte (×109/L) 3.8-11.5 5.52 ± 0.26 5.53 ± 0.33 5.94 ± 0.33 5.83 ± 0.40 5.44 ± 0.31 6.14 ± 0.34 5.68 ± 0.24 5.48 ± 0.22 6.04 ± 0.23
Neutrophil (×109/L) 2.5-7.5 3.21 ± 0.17 3.15 ± 0.25 3.46 ± 0.24 3.54 ± 0.31 2.96 ± 0.21 3.71 ± 0.25 3.38 ± 0.18 3.05 ± 0.16 3.59 ± 1.73
Lymphocyte
(×109/L)
1.5-4 1.70 ± 0.11 1.74 ± 0.12 1.80 ± 0.10 1.74 ± 0.12 1.92 ± 0.10 1.82 ± 0.13 1.72 ± 0.08 1.83 ± 0.08 1.81 ± 0.08
Monocyte (×109/L) 0.2-0.8 0.33 ± 0.02 0.33 ± 0.30 0.35 ± 0.02 0.29 ± 0.02 0.27 ± 0.20 0.30 ± 0.03 0.31 ± 0.01 0.30 ± 0.02 0.33 ± 0.02
Eosinophil (×109/L) 0.05-0.5 0.15 ± 0.02 0.18 ± 0.03 0.16 ± 0.02 0.12 ± 0.02 0.16 ± 0.03 0.13 ± 0.02 0.14 ± 0.01 0.17 ± 0.02 0.14 ± 0.01
Basophil (×109/L) 0.01-0.15 0.017 ± 0.00 0.017 ± 0.00 0.025 ± 0.00 0.015 ± 0.00 0.015 ± 0.00 0.025 ± 0.00 0.016 ± 0.00 0.016 ± 0.00 0.025 ± 0.00*
Data present the mean ± standard error of the mean of the white blood cells numbers for each group and time point. Friedman test was applied to determine intergroup
differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline). *p ≤ 0.05.
Table 7. Physical and mental self-perception (SF-36 health survey).
Males Females Total
Baseline Day 28 Baseline Day 28 Baseline Day 28
Physical health
Physical functioning 99.33 ± 0.45 99.67 ± 0.33 95.29 ± 3.28 95.29 ± 3.25 97.19 ± 1.77 97.34 ± 1.75
Role limitations due to physical health 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 91.18 ± 6.41 100.00 ± 0.00 95.31 ± 3.45
Pain 92.00 ± 2.43 93.67 ± 3.06 88.23 ± 3.53 83.23 ± 4.87 90.00 ± 2.18 88.12 ± 3.06
General health 88.33 ± 1.99 88.00 ± 1.81 78.23 ± 3.90 79.71 ± 3.77 82.97 ± 2.42 83.59 ± 2.27
Mental health
Social functioning 93.33 ± 3.63 92.50 ± 3.18 97.79 ± 1.60 94.12 ± 2.17 95.70 ± 1.91 93.36 ± 1.86
Role limitations due to emotional problems 88.89 ± 5.31 86.67 ± 7.83 92.16 ± 5.37 98.04 ± 1.96 90.62 ± 3.74 92.71 ± 3.88
Energy/fatigue 62.67 ± 3.54 60.17 ± 4.29 64.71 ± 3.14 67.79 ± 2.34 63.75 ± 2.32 64.22 ± 2.42
Emotional well-being 55.47 ± 3.09 58.67 ± 3.81 55.76 ± 3.44 58.12 ± 2.41 55.62 ± 2.29 58.37 ± 2.16
Global health status 58.33 ± 3.98 56.25 ± 4.27 54.41 ± 3.20 55.88 ± 3.41 56.25 ± 2.51 56.06 ± 2.67
Data represent the mean ± standard error of the mean of the scores obtained by the Short Form-36 (SF-36) health survey for each group and time point. Wilcoxon test was
applied to determine difference for values obtained at each time point in all volunteers or discriminated by sex.
the study, by means of the SF-36 health survey. Although there
are several clinical studies that assess the beneficial effects of
lupine proteins,[23–27] no data about health status perception was
previously reported. The unchanging effects on general, hepatic,
and renal biochemical markers as well as on hemogram and the
health survey (SF-36) allow us to conclude that the 28-day inges-
tion of the LPHb was safe as no side effects on their metabolism
(biochemical markers) or discomfort (SF-36) were observed in
the volunteers enrolled in the study.
Beside the safety, the efficacy of LPHbwas explored. Regarding
the cellular immune response, the LPHb consumption reduced
the PHA-induced Th1 pro-inflammatory response in PBMCs
Table 8. Lipid biochemical parameters.
Range Males Females Total
Baseline Day 14 Day 28 Baseline Day 14 Day 28 Baseline Day 14 Day 28
TC (mg dL−1) 150-200 159.33 ± 6.66 154.87 ± 7.76* 157.12 ± 6.84 168.06 ± 7.18 165.31 ± 6.05 162.62 ± 5.63 163.97 ± 4.91 163.15 ± 5.67 159.87 ± 4.39
HDL-C (mg dL−1) 39-60 53.25 ± 3.70 49.19 ± 2.98 52.81 ± 3.43 66.87 ± 1.97 69.53 ± 2.10 65.71 ± 2.45 60.06 ± 2.40 59.67 ± 2.52 59.45 ± 2.35
LDL-C (mg dL−1) 80-140 96.62 ± 8.00 91.37 ± 6.40 88.87 ± 5.44 84.27 ± 5.82 90.53 ± 7.32 89.73 ± 8.21 92.62 ± 5.27 90.94 ± 4.81 89.29 ± 4.78
TG (mg dL−1) 70-170 69.40 ± 7.91 71.44 ± 6.99 77.19 ± 6.40 55.88 ± 4.53 54.53 ± 4.11 73.76 ± 8.27 62.22 ± 4.51 62.73 ± 4.20 72.56 ± 4.48
LDL-C/HDL-C
ratio
0-3 1.99 ± 0.23 1.94 ± 0.17 1.68 ± 0.14** 1.34 ± 0.10 1.32 ± 0.11 1.39 ± 0.14 1.67 ± 0.14 1.62 ± 0.11 1.60 ± 0.12*
Data present the mean ± standard error of the mean of lipid biochemical parameters values for each group and time point. Friedman test was applied to determine intergroup
differences for the values obtained at each time point in all volunteers and discriminated by sex. Statistical significance with respect to day 0 (baseline). HDL-C, high-density
lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides. *p ≤ 0.05 and **p ≤ 0.01.
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Figure 2. Lipid profile analysis of male volunteers with a possible risk of suffering cardiovascular diseases. Mean ± standard error of the mean of lipid
biochemical parameters (TC, LDL-C, and LDL-C/HDL-C ratio) quantified at the start (day 0) and end of the study (day 28), calculated according to
whether they were below (M1) or above (M2) the median of baseline values for each parameter considered as a risk factor for cardiovascular diseases.
Risk factors considered were: BMI (A), total cholesterol (B), LDL-C (C), Castelli risk I (D) and II (E), and atherogenic index of plasma (F). Only the male
population was considered (n = 15). *p ≤ 0.05; **p ≤ 0.01 between day 28 and the control condition (day 0, before starting the study). BMI, body mass
index; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol, TC, total cholesterol; TG, triglycerides.
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Figure 3. Cytokine production in PHA-stimulated PBMCs after 48 h of cul-
ture. Pro-inflammatory (A–C) and anti-inflammatory cytokines (D,E), ra-
tios between IL-10 and pro-inflammatory cytokines (F–H) and between
IL-4 and pro-inflammatory cytokines (I–K) were shown. Data presented as
mean ± standard error of the mean of each group. Statistical significance
with respect to the control group, *p ≤ 0.05; **p ≤ 0.01. IFN-𝛾 , interferon-
𝛾 ; IL, interleukin; TNF, tumor necrosis factor.
Figure 4. Antioxidant capacity. Total antioxidant capacity in µM copper re-
ducing equivalents A) and oxygen radical absorbance capacity (ORAC) in
mmoles of Trolox equivalents/mL B) were quantified at days 0 and 28 time
points. Data presented as mean ± standard error of the mean of each
group values obtained at each time point. Statistical significance with re-
spect to the control group (day 0, baseline), *p ≤ 0.05.
from participants whereas the Th2 response was not modified,
skewing the Th1/Th2 balance toward an anti-inflammatory mi-
croenvironment. This finding agrees with our previous results
that showed the anti-inflammatory bias of the T response on
human PBMCs in vitro treated with LPHs.[14] However, this is
the first report to show this effect on the T cell response after
in vivo ingestion of LPHb. In this way, clinical evidence of the
effect of vegetable proteins hydrolysates on the human immune
status are very limited. A previous study showed that the intake
of 3 g gluten hydrolysates for 6 days was able to increase natural
killer (NK) cells activity without reporting side effects by the five
enrolled healthy volunteers.[28] Moreover, a single oral dose of 8 g
soybean protein hydrolysate modulated the frequency of blood
leukocytes in 10 healthy volunteers by a transient increase of NK
cells and macrophages and a decrease of B cells.[29] Therefore, to
our knowledge, this is the first study to address the immunomod-
ulatory role of LPHb in human leukocytes in a longitudinal trial.
In addition to cytokines, oxidative molecules such as reactive
oxygen species (ROS) can be released from inflammatory cells
at the site of inflammation.[30] Although the ROS generation is
a physiological process, it is widely known that oxidative stress
is generated by an imbalance between ROS production and the
antioxidant capacity of the system that leads to an exacerbated ac-
cumulation of free radicals that can result in cellular damage.[31]
Several enzymatic and non-enzymatic antioxidant mechanisms
are key elements involved in the control of the intracellular
reduction-oxidation balance by ROS detoxification.[32] The an-
tioxidant status of PBMCs from the volunteers was significantly
higher after 28 days LPHb intake, quantified both by TAC, an
assay based on the determination of the copper reduction by a
biological sample,[33] and by ORAC, an assay that quantify the
neutralizing capacity against oxidation induced by the peroxyl
radical.[34] These results agree with our previous studies,[14]
showed the improvement of cell antioxidant capacity of vol-
unteers after the LPHb consumption. Lupine or pea protein
hydrolysates obtained with commercial proteases (alcalase, neu-
trase, and flavourzyme) have recently been shown not to increase
TAC in respect to the control group (raw flour of lupine or pea,
respectively).[35] However, after chromatographic separation, a
sequence with antioxidant capacity was found, suggesting that
the generation of the bio-functional peptides depends on the
type of hydrolysis (chemical or biological hydrolysis), type of pro-
teases, and the reaction duration.[35] No specific studies about the
lupine effects on ORAC have been reported. To our knowledge,
there is no study on the antioxidant status of PBMCs after a treat-
ment with a vegetable functional food. This is the first work that
describes the increased antioxidant status of human circulating
leukocytes after the in vivo ingestion of a lupine-based functional
food.
In addition to the immunomodulatory and anti-oxidant roles
of the LPHb in the PBMCs of volunteers, the intake of the bever-
age showed a significant reduction in the LDL-C/HDL-C ratio,
which is considered as one of the most accurate predictors of
cardiovascular diseases (CVDs),[36] supporting a possible cardio-
vascular protective effect of the lupine hydrolysate. This effect
was specifically due to the male population, which is notewor-
thy, giving that age-adjusted CVDs mortality rates are higher in
males compared to females.[37]
In vitro studies have reported the positive influence of lupine
peptides on cholesterol metabolism.[38,39] Moreover, several stud-
ies have reported the regulation of the lipid profile by lupine
proteins in hypercholesterolemic adults. Different lupine pro-
tein enriched-foods (25–30g in bars, beverages, etc.), consumed
for 4 weeks, reduce TC and LDL-C.[23,25,40] These positive ef-
fects have also been observedwith L. angustifolius proteins.[24,41,42]
On the contrary, consumption of lupine flour-enriched foods
(bread, pasta or biscuits) during a 1 year controlled trial
was reported not to affect the lipid parameters.[43] Other veg-
etable compounds have also demonstrated a cholesterol-lowering
effect.[26,44]
Interestingly, the present study is the first to show that the
daily ingestion of a LPHb containing 1 g of Alcalase 2.4 L-
generated L. angustifolius hydrolysates for 4 weeks is enough
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to significantly reduce the LDL-C/HDL-C ratio in normocholes-
terolemic male subjects, which supports the idea that protein hy-
drolysates are more bioactive than intact protein or free amino
acids [45] due to the fact that the protein hydrolysis generates
short peptides that are easily digestible.[46] In this regard, L. al-
bus hydrolysates obtained by pepsin and trypsin digestion were
reported to interfere with de novo cholesterol synthesis and in-
crease LDL-C uptake in a human hepatocyte cell line (HepG2 cell
line).[39]
Hypertension, together with increased values of BMI, TC,
LDL-C, and LDL-C/HDL-C and TC/HDL-C ratios are defined
as risk factors of endothelial dysfunction and, consequently, of
cardiovascular risk.[47,48] In addition to lipid parameters, lupine-
enriched food consumption has also shown antihypertensive
activities.[43,49] The present trial revealed that males who pre-
sented high baseline CVDs risk factors underwent a remark-
able decrease in cholesterol-related parameters after 28 days of
LPHb consumption, supporting further approaches in patholog-
ical conditions related to hypercholesterolemia. Therefore, based
on previous considerations, LPHb could be a suitable candidate
to develop plant-based functional foods.
The main contribution of this study is that this is the first
to show that the daily ingestion for 28 days of lupine bioac-
tive peptides-based functional food is not only safe but also
effective controlling key steps of several pathologies such as
inflammation, oxidative stress and cholesterol metabolism,
supporting the further evaluation of LPHs-based products in
clinical conditions. However, our study has certain limitations,
the most important being the absence of a control group as
it is a before-and-after intervention where the baseline values
of each volunteer were considered self-controlled. The placebo
effect could influence our results; however, we speculate that
the efficacy outcomes of this study such as inflammatory and
antioxidant responses of peripheral leukocytes are difficult to be
modified by placebo effect. It would even be less likely that the
placebo effect is responsible for the beneficial effects of LPHb on
reducing cholesterol levels and LDL-C/HDL-C index in people
who present a higher baseline level of biochemical markers of
cardiovascular risk. However, although blood markers are less
likely to be affected by the placebo effect than more subjective
measures (such as a survey), we cannot absolutely rule out the
placebo effect. Although this experimental design is weaker
than a randomized controlled trial with respect to establishing a
cause-effect relationship, before-and-after approaches have been
widely used.[50–54] Moreover, the present single-group before-
after design could be biased by the modification of the subjects’
lifestyle (Hawthorne effect). According to previous studies
protocols,[55–59] participants were instructed not to modify their
dietary and physical habits. Thus, they followed their typical
eating and drinking habits and physical training throughout the
trial. In fact, it is important to note that no impact in the weight of
volunteers was observed after 28 days of beverage intake, which
could indirectly suggest no change in eating habits or physical
activity.
Furthermore, no changes in the physical or mental self-
perception (SF-36 health survey) were observed by volunteers by
means after LPHb ingestion. Furthermore, although Hawthorne
and placebo effects are a limitation of this type of experimen-
tal design, the short period of the trial (28 days) also minimizes
the probability that changes in the parameters studied are due
to the subjective perception of the volunteers. Another fact that
could support the causal effects of LPHb is that our results agree
with previous in vitro studies showing the improvement of im-
mune and antioxidant status as well as the hypocholesterolaemic
effects driven by lupine peptides.[12–14,38,39] On the other hand,
a single-group before-after design allows us to double the num-
ber of participants in the study compared to a placebo-controlled
design.
In conclusion, this study reports that a 4-weeks daily intake of
a functional beverage based on Alcalase 2.4 L-generated lupine
protein hydrolysates is safe and effective in both reducing the pro-
duction of Th1 pro-inflammatory cytokines and increasing the
anti-inflammatory/pro-inflammatory microenvironment of the
PHA-stimulated PBMCs, as well as increasing the cellular antiox-
idant capacity in healthy subjects. In addition, the beverage intake
reduces the LDL-C/HDL-C atherogenic index and, noteworthy,
its particularly beneficial capacity in decreasing TC, LDL-C, and
LDL-C/HDL-C index in the male cohort that showed high base-
line levels of well-known cardiovascular risk factors such as BMI,
TC, LDL-C, Castelli risk index I and II and the atherogenic index
of plasma. Therefore, this is the first study of the pleiotropic ac-
tions of a lupine bioactive peptides-based functional food on key
steps of atherosclerosis including inflammation, oxidative stress
and cholesterol metabolism.
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